Study to Evaluate Effects of INL1 in Patients With Heart Failure and Reduced Ejection Fraction
Status:
Recruiting
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, randomized, double-blind, placebo-controlled, dose-response trial in
patients with chronic stable Heart Failure (HF) and reduced Left Ventricular Ejection
Fraction (LVEF) to evaluate the efficacy and safety of three INL1 doses compared with
placebo. Patients will be treated for approximately 12 weeks with one of three INL1 doses: 50
mg, 150 mg, 300 mg, or, placebo capsules, taken twice daily (BID).